Description
Zelnorm (Tegaserod) is an oral drug prescribed for the short-term treatment of women who suffer from irritable bowel syndrome with primary symptom as constipation. It can be taken with other medicines as up to date there are no known drug interactions with tegaserod. However, if used with other solutions which increase intestinal contractions, it may cause more of diarrhea.
Related Themes:
Women's Health
Female enhancement pills are medications specially designed for women to solve their sexual problems. It’s not a secret that a woman’s libido is a much more complicated issue than libido of a man. The men’s libido is mainly physical, whereas female libido depends on a number of factors. It explains why the ways of managing the conditions related to the problems of female’s libido are also rather sophisticated. For women it’s important to have a harmonious balance of hormones and … Continue reading →
Today only one non-prescription weight-loss medication is approved for dealing with the excess weight – this is a reduced-dose preparation of Orlistat which is called Alli. This medication helps to absorb certain amount of ingested fat. Compare to prescription Orlistat, Alli has fewer side effects. Nevertheless, certain side effects might appear such as oily stools and discharge and other bowel disorders. According to the studies, weight loss effect using Alli is about 50% greater than following a diet and doing … Continue reading →
Zelnorm
Gastro-intestinal disorders can bring a lot of discomfort and pain. Some of these conditions might prevent people from participating in physical activities, others from being able to eat different food without experiencing painful burning sensation and acid reflux. Fortunately, gastro-intestinal medications help to get rid of such symptoms. Moreover, gastrointestinal drugs help to smooth the unfavourable effect of other medicines, for example, the negative influence of drug therapies such as chemotherapy by providing anti-nausea and vomiting effects. These medications can … Continue reading →
